Profile data is unavailable for this security.
About the company
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis and plans to initiate additional Phase 2 trials in other neuromuscular indications, including Multifocal Motor Neuropathy and Chronic Inflammatory Demyelinating Polyneuropathy. Its product candidate, DNTH103, is a clinical-stage, highly potent, highly selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of the C1s complement protein. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile.
- Revenue in USD (TTM)4.12m
- Net income in USD-56.68m
- Incorporated2015
- Employees53.00
- LocationDianthus Therapeutics Inc300 Technology Square, 8Th FloorCAMBRIDGE 02139United StatesUSA
- Phone+1 (857) 201-2700
- Fax+1 (302) 655-5049
- Websitehttps://dianthustx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Savara Inc | 0.00 | -75.29m | 763.75m | 37.00 | -- | 6.30 | -- | -- | -0.4317 | -0.4317 | 0.00 | 0.7361 | 0.00 | -- | -- | 0.00 | -58.02 | -36.86 | -62.14 | -39.54 | -- | -- | -- | -102,587.50 | -- | -- | 0.2066 | -- | -- | -- | -43.38 | -- | 15.91 | -- |
Replimune Group Inc | 0.00 | -220.01m | 767.25m | 331.00 | -- | 1.80 | -- | -- | -3.27 | -3.27 | 0.00 | 6.24 | 0.00 | -- | -- | 0.00 | -38.64 | -29.08 | -41.09 | -30.56 | -- | -- | -- | -- | -- | -- | 0.143 | -- | -- | -- | -23.82 | -- | 16.84 | -- |
Olema Pharmaceuticals Inc | 0.00 | -109.63m | 778.82m | 80.00 | -- | 3.43 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Arbutus Biopharma Corp | 10.06m | -77.09m | 781.56m | 73.00 | -- | 6.38 | -- | 77.68 | -0.4416 | -0.4416 | 0.0575 | 0.6488 | 0.0597 | -- | 4.59 | 137,821.90 | -45.77 | -52.62 | -53.21 | -58.11 | -- | -- | -766.20 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 787.25m | 107.00 | -- | 2.50 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Stoke Therapeutics Inc | 15.16m | -103.57m | 797.09m | 110.00 | -- | 3.26 | -- | 52.59 | -2.18 | -2.18 | 0.317 | 4.64 | 0.0537 | -- | 68.74 | 137,790.90 | -36.68 | -31.62 | -41.57 | -33.92 | -- | -- | -683.31 | -1,775.50 | -- | -- | 0.00 | -- | -29.22 | -- | -3.59 | -- | 11.56 | -- |
AbCellera Biologics Inc | 33.06m | -153.30m | 807.38m | 586.00 | -- | 0.7267 | -- | 24.43 | -0.5254 | -0.5254 | 0.1133 | 3.77 | 0.0224 | -- | 0.808 | 56,407.85 | -10.39 | 6.08 | -11.11 | 6.67 | -- | -- | -463.77 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
Arrivent Biopharma Inc | 0.00 | -74.89m | 812.78m | 40.00 | -- | 2.73 | -- | -- | -2.46 | -2.46 | 0.00 | 8.85 | 0.00 | -- | -- | 0.00 | -29.50 | -- | -31.02 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
Dianthus Therapeutics Inc | 4.12m | -56.68m | 824.86m | 53.00 | -- | 2.30 | -- | 200.31 | -5.54 | -5.54 | 0.2092 | 12.20 | 0.0184 | -- | -- | 77,698.11 | -25.33 | -41.40 | -26.15 | -44.70 | -- | -- | -1,376.42 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
Erasca Inc | 0.00 | -158.28m | 839.04m | 126.00 | -- | 1.80 | -- | -- | -0.9207 | -0.9207 | 0.00 | 1.65 | 0.00 | -- | -- | 0.00 | -32.76 | -- | -34.48 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
Terns Pharmaceuticals Inc | 0.00 | -95.90m | 847.37m | 66.00 | -- | 3.23 | -- | -- | -1.31 | -1.31 | 0.00 | 3.11 | 0.00 | -- | -- | 0.00 | -36.84 | -41.34 | -38.72 | -45.70 | -- | -- | -- | -31,010.30 | -- | -- | 0.00 | -- | -- | -- | -49.49 | -- | -26.60 | -- |
Silence Therapeutics plc | 23.78m | -53.27m | 854.34m | 115.00 | -- | 5.62 | -- | 35.93 | -0.4282 | -0.4282 | 0.1899 | 1.06 | 0.1273 | -- | 2.56 | 206,778.60 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Oruka Therapeutics Inc | 0.00 | -7.20m | 868.66m | 4.00 | -- | 0.9211 | -- | -- | -5.97 | -5.97 | 0.00 | 26.94 | 0.00 | -- | -- | 0.00 | -19.22 | -27.78 | -19.99 | -29.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 46.21 | -- | -- | -- |
89bio Inc | 0.00 | -174.61m | 877.99m | 70.00 | -- | 1.69 | -- | -- | -1.97 | -1.97 | 0.00 | 4.91 | 0.00 | -- | -- | 0.00 | -32.50 | -45.50 | -34.68 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0465 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
Holder | Shares | % Held |
---|---|---|
Fidelity Management & Research Co. LLCas of 30 Jun 2024 | 4.17m | 14.20% |
Avidity Partners Management LPas of 30 Jun 2024 | 2.92m | 9.94% |
Fairmount Funds Management LLCas of 30 Jun 2024 | 2.76m | 9.41% |
RA Capital Management LPas of 30 Jun 2024 | 2.33m | 7.95% |
Octagon Capital Advisors LPas of 30 Jun 2024 | 1.75m | 5.95% |
BlackRock Fund Advisorsas of 30 Jun 2024 | 1.46m | 4.98% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 1.22m | 4.15% |
Great Point Partners LLCas of 30 Jun 2024 | 757.93k | 2.58% |
Janus Henderson Investors US LLCas of 30 Jun 2024 | 675.66k | 2.30% |
RTW Investments LPas of 30 Jun 2024 | 666.67k | 2.27% |